Author: Ravi Shankar

ICG Enterprise Trust plc (the “Company”)

13 November 2026

Transaction in Own Shares

The Company announces that on 12 November 2026 it bought back 10,000 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1396 pence per share.

Further details are set out below:

• Number of shares held as treasury shares following settlement of this purchase: 3,712,500
• Total shares in issue excluding treasury shares following settlement of this purchase: 59,841,692

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Limited Announces the Notice of Extraordinary General Meeting

St Peter Port, Guernsey, 13 November 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) announces that an Extraordinary General Meeting (“EGM”) will be held at 10:00am on the 1st December 2026, at Ground Floor, Mill Court, La Charroterie, St Peter Port, Guernsey, GY1 1EJ.

Since the Company’s last Annual General Meeting held on 11 June 2026 (the “2026 AGM”), the Company has continued to undertake regular and accretive buybacks of Class A Shares, repurchasing 5,606,936 Class A Shares as of the Latest Practicable Date representing 88.7 per cent. of the 2026 AGM Authority.

Therefore, the Board is proposing that the buyback authority is refreshed to ensure the Company has the flexibility to continue to buy back Class A Shares before its next annual general meeting.

The Company’s capital allocation framework is made up of two pillars: (1) allocating capital to the Company’s investment programme to drive long-term NAV growth, and (2) returning capital to Shareholders in the form of dividends and Share buybacks. The flexibility of this framework is a direct result of the Company’s co-investment model which allows the Board to allocate capital dynamically across both pillars, depending on market conditions and realisation outlook.

Since 1 January 2026, the Company has continued to allocate capital across both pillars. In the 10 months to 31 October 2026, $185 million of capital has been committed in 10 new investments, which are expected to be the engine for medium to long-term NAV growth. Alongside new investment activity, $182 million has been returned to Shareholders through dividends ($40 million) and Share buybacks ($142 million), a 78% increase from the 12 months to 31 December 2025¹. The increase in Share buybacks reflects the Board’s confidence in the portfolio and its prospects, the Share price undervaluation of the portfolio, and the NAV per Share accretion opportunity that buybacks present. In the 9 months to 30 September 2026, Share buybacks have resulted in a $1.05 accretion to NAV per Share.

This increase in new investment pace and returns of capital has been supported by significant distributions from the portfolio, both from organic exits and proactive portfolio management, with $299 million of realisations from signed transactions announced to 30 September 2026, of which $195 million of proceeds had been received by that date.

The Notice of EGM will be dispatched to all shareholders and an electronic copy of the Notice of EGM will also be available on the Company’s website Neuberger Private Equity Partners and at the National Storage Mechanism website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

Defined terms used in this announcement have the same meaning as set out in the Notice of EGM.

For further information, please contact:

NBPE Investor Relations  +44 20 3214 9002

Luke Mason NBPrivateMarketsIR@nb.com  

Highvern Fund Services Limited +44 1481 668 732

hfslnbpep@highvern.com 

About Neuberger Private Equity Partners Limited

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger’s investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again this past year, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards.

Data as of March 31, 2026.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

All Neuberger figures are as of March 31, 2026, unless otherwise noted, and are subject to change without notice. The firm data, including employees and assets under management, reflect the collective data of the various affiliated investment advisors who are subsidiaries of Neuberger Berman Group LLC. The company history/timeline includes the history of all the company’s subsidiaries, including predecessor companies and acquisitions.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

---

¹ As of 31 October 2026, inclusive of cash settlements through 3 November 2026.

KALMAR CORPORATION, TRADE PRESS RELEASE, 13 NOVEMBER 2026 AT 9:00 (EET)

Kalmar to supply its first customised electric reachstacker with side-tilt spreader and hydraulic slab gripper to POK Zachód in Poland

Kalmar has secured an order to supply a customised Kalmar electric reachstacker to POK Zachód sp. z o.o. in Wojkowice, Poland for its steel and container handling logistics. The order was booked in Kalmar’s Q3 2026 order intake, with delivery scheduled for Q2 2027.

The new Kalmar electric reachstacker with lifting capacities of up to 45 tonnes and a 533 kWh nominal capacity battery pack will be used for demanding container and steel handling operations at the customer’s POK Zachód terminal. To address its specific material handling requirements, the machine will be tailored with a special 55-degree side tilt spreader designed to empty bulk-loaded containers, alongside a hydraulic operated steel slabs gripper capable of handling loads up to 33 tonnes. This marks the first-ever Kalmar electric reachstacker built with both a side-tilting spreader and a hydraulic slab gripper.

The project is co-financed by the European Union under the Just Transition Fund (FST).

Marcin Woźniak, President of the Management Board, POK Zachód: “We are proud to take this important step in transitioning our operations toward zero emissions. Kalmar proved to be the ideal partner due to its strong brand recognition in the market, impressive customer references, and ability to customise an advanced electric reachstacker specifically to meet our needs.”

Jakub Wojciechowski, Country Director, Kalmar Poland: “We are delighted to welcome POK Zachód as our new customer. This order highlights our ability to tailor standard equipment into specialised, high-level solutions for demanding customer applications. We would like to extend special thanks to Frederik Malmborg for his exceptional sales support in bringing this innovative solution to life.”

Further information for the press:

Jakub Wojciechowski, Country Director, Kalmar Poland, jakub.wojciechowski@kalmarglobal.com   

Kalmar (Nasdaq Helsinki: KALMAR) is moving goods in critical supply chains around the world, with the vision to be the forerunner in intelligent and sustainable heavy material handling solutions. The company offers a wide range of industry shaping heavy material handling equipment and services to ports and terminals, distribution centres, manufacturing and heavy logistics. Headquartered in Helsinki, Finland, Kalmar operates globally in over 120 countries and employs approximately 5,300 people. In 2025, the company’s sales totalled approximately EUR 1.7 billion. www.kalmarglobal.com 

Attachment

• Kalmar electric reachstacker

• All participants showed cutaneous neurofibroma (cNF) reductions: All 15 evaluable participants had reductions in target cNF surface area, with a median best reduction of 41% across all doses and 46% at doses planned for Phase 2
• cNF reductions deepened with continued treatment: The median reduction in target cNF surface area reached 49% at Cycle 12 among participants followed through 12 cycles and 71% at Cycle 15 in the 4mg cohort
• Favorable safety and tolerability profile: No treatment related serious adverse events, treatment related discontinuations, retinopathy or adverse event of decreased left ventricular ejection fraction (LVEF)
• IND cleared for Phase 2 in cNF: The FDA’s Division of Dermatology and Dentistry has cleared the IND for a Phase 2 trial of PAS-004 in adults with NF1-associated cNF
• Early activity in plexiform neurofibromas (PN): Reductions in target PN volume observed in all 18 evaluable participants, including two with reductions ≥20%, one achieving a 22.5% reduction at the first on-treatment MRI (Cycle 4)
• PAS-004 Clinical Data Webcast: Pasithea will post a webcast on Friday, November 13, 2026, at 7:00 a.m. EST to discuss the data presented at the European Neurofibromatosis Conference

MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced positive clinical data from its ongoing Phase 1/1b study in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) and a subset of patients with cutaneous neurofibromas (cNF) (Study PAS-004-103, NCT06961565), presented at the 2026 European Neurofibromatosis Conference in Vienna, Austria.

“Cutaneous neurofibromas do not regress spontaneously and generally increase in number and size with age. The substantial reductions in cNF size reported today represent an encouraging clinical signal in a condition for which there are currently no FDA-approved systemic treatments,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “Importantly, these reductions have continued to deepen with longer treatment, including at the lowest doses tested. With our IND now cleared by FDA’s Division of Dermatology and Dentistry, these findings reinforce our confidence in the 4mg to 12mg dose range planned for Phase 2 and support advancing PAS-004 into a randomized, placebo-controlled study in cNF.”

“The reductions in cNF size observed with oral PAS-004 highlight its potential to provide broad, visible improvements for patients through a systemic treatment approach, rather than relying on local procedures that can treat individual lesions,” said Dr. Kartik Krishnan, Chief Medical Officer of Pasithea. “We are also seeing early activity in plexiform neurofibromas, with reductions in tumor volume across all dose levels and two participants meeting the REiNS threshold for partial response, including one at the first on-treatment MRI. Together with the favorable tolerability observed to date and a pharmacokinetic profile characterized by a 40-to-60-hour half-life and limited peak-to-trough fluctuations, these findings support the continued development of PAS-004 as a once-daily oral therapy for long-term treatment of NF1-associated neurofibromas.”

Pasithea will post a webcast on Friday, November 13, 2026, at 7:00 a.m. EST to discuss the PAS-004 clinical data presented at the 2026 European Neurofibromatosis Conference. The webcast will be accessible here and through the Investors section of the Company’s website.

Study Overview

Study PAS-004-103 is an ongoing multicenter, open-label Phase 1/1b trial in adults with NF1 and symptomatic and inoperable, incompletely resected, or recurrent PN at five sites in the United States, Australia and South Korea. The study also evaluates up to 7 cNFs in participants with measurable lesions. Part A studies six escalating doses using a 3+3 design to select two doses for evaluation in Part B, a randomized dose expansion phase. The study also assesses safety, tolerability, pharmacokinetics and pharmacodynamics.

As of September 15, 2026, 19 participants have been enrolled across six cohorts (4, 8, 12, 15, 18 and 24mg). Of these, 15 were evaluable for cNF and 18 for PN response. Median treatment duration ranged from 14.4 months at 4mg to approximately 4 months at 15mg and 24mg. One participant discontinued by sponsor decision for noncompliance, unrelated to safety.

Cutaneous Neurofibroma (cNF) Data

Fifteen participants were evaluable for cNF, with 71 target cNFs measured at baseline. Length and width of each target cNF were measured in triplicate with digital calipers. As there is no regulatory standard for assessing cNFs, both surface area (calculated from length and width) and longest diameter (the REiNS-recommended caliper measure) are reported.

Substantial Reductions in cNF Surface Area (Figure 1)

Reductions Across All Doses: All 15 evaluable participants showed reductions in summed target cNF surface area at best response, with a median best reduction of 41%.

Activity at Planned Phase 2 Doses: Among eight evaluable participants treated at 4, 8 and 12mg, the median best reduction was 46%. All six participants treated at 4mg and 8mg achieved reductions greater than 40%.

Figure 1: Best change from baseline in summed target cNF surface area by participant, grouped by dose cohort (N = 15). Data cut-off October 7, 2026.

cNF Reductions Deepened with Continued Treatment (Figure 2)

Among participants followed through 12 treatment cycles, the median reduction in summed target cNF surface area increased from 12% at Cycle 1 to 38% at Cycle 4 and 49% at Cycle 12. In the 4mg cohort, the median reduction reached 71% at Cycle 15.

Figure 2. Change in summed target cNF surface area over time by participant and dose cohort. Dashed lines indicate 20% and 37% reduction thresholds (37% area ≈ 50% volume). Data cut-off: October 7, 2026.

Consistent Findings Using Longest-Diameter Measurements (Figure 3)

At the 4, 8 and 12mg doses planned for the Phase 2 trial, 27 of 37 target cNFs (73%) were reduced by at least 25% in longest diameter, meeting the REiNS shrinkage criterion. Eight of the 37 target cNFs were surgically resected (red ovals) for pharmacodynamic analysis at either Cycle 1 or Cycle 6 and could not be assessed thereafter; they are included with their last measurement before resection. Among the 29 cNFs that were not resected, 24 (83%) met the REiNS criterion, with a median best reduction in longest diameter of 39%.

Figure 3. Best change in target cNF longest diameter at 4, 8 and 12mg (37 target cNF from 8 participants). Red ovals identify the target cNF resected for pharmacodynamic analysis; dashed line indicates the REiNS 25% shrinkage threshold. Data cut-off: October 7, 2026.

Early Activity in Plexiform Neurofibromas (Figure 4)

All 18 evaluable participants showed reductions in target PN volume by blinded independent central review, including two who met the REiNS partial-response threshold at 12mg and 15mg. The 15mg participant achieved a 22.5% reduction at the first on-treatment MRI, pending confirmation on a subsequent scan.

Figure 4. Best change in target PN volume by participant and dose cohort, based on blinded independent central review (N = 18). Dashed line indicates the REiNS 20% partial-response threshold. MRI data cut-off September 30, 2026.

Safety and Tolerability

No treatment-related serious adverse events, discontinuations, adverse events of decreased LVEF, or cases of retinopathy have been reported. Most treatment-related adverse events were Grade 1 or 2 (97.6% of events). The two Grade 3 treatment-related events were asymptomatic increases in blood creatine phosphokinase (CPK), both of which resolved following a one-week dose interruption, with both participants continuing treatment. At the 4 to 12mg doses planned for Phase 2, dermatitis acneiform (rash) and diarrhea occurred in 33% and 11% of participants, respectively (data cut-off: September 15, 2026).

Pharmacokinetics

PAS-004 showed approximately dose-proportional exposure across the 4 to 24mg range, a terminal half-life of 40 to 60 hours, and limited peak-to-trough fluctuations (Cmax/Cmin of 1.5 to 2.0), consistent with findings from the Company’s ongoing Phase 1 study in advanced solid tumors and supporting once-daily dosing (data cut-off: October 7, 2026).

Next Steps

The FDA’s Division of Dermatology and Dentistry has cleared the IND for Study PAS-004-201, a randomized, double-blind, placebo-controlled Phase 2 trial evaluating three once-daily doses of PAS-004 in approximately 200 adults with NF1-associated cNF.

The ongoing Phase 1/1b study (PAS-004-103) will continue participant follow-up and advance toward Part B, a randomized two-dose expansion phase. The Company expects to complete pharmacodynamic analyses of resected cNFs in 2027 and present additional clinical data at future scientific meetings.

About Cutaneous Neurofibromas (cNF)

NF1-associated cutaneous neurofibromas (cNFs) are benign tumors that grow in or just beneath the skin at virtually any location in the body and are a hallmark of NF1. It is a serious condition and cNFs are associated with significant morbidity that can have substantial impact on day-to-day functioning, leading patients to rate this as the most significant burden of NF1 despite other potentially life-threatening complications. cNF typically begin to appear in adolescence, generally increase in number and volume with age. The number of cNFs on an individual patient can range from a few to thousands. Although malignant transformation does not occur with NF1-associated cNF, cNFs are present in over 95% of individuals with NF1 and have a significant negative impact both physically, with disfigurement, and on health-related quality of life. Current management relies largely on procedural approaches such as surgical excision, electrodesiccation, or laser therapy. There are no FDA-approved systemic therapies for the treatment of NF1-associated cNF.

About Plexiform Neurofibromas (PN)

NF1-associated plexiform neurofibromas (PNs) are tumors originating from the nerve sheath that grow through and around nerves and may involve multiple nerve branches. Thirty to fifty percent (30-50%) of patients with NF1 will harbor PNs, which can undergo malignant transformation. PN-related morbidities, including pain, disfigurement and functional impairment are primarily caused by the direct impact of the tumor on surrounding structures and can be life-threatening when they compress vital organs or when they become malignant.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated cutaneous and plexiform neurofibromas (NCT06961565).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s clinical data from Study PAS-004-103 in cNF and PN, including response rates, durability, and safety observations, and their significance, the Company’s planned Phase 2 study of PAS-004 in cNF and the FDA’s clearance of the Company’s IND to proceed with such study, the Company’s clinical data from its Phase 1 dose-escalation study of PAS-004 in advanced solid tumors, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, including other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks related to the initiation, design, timing, enrollment, and conduct of clinical trials and interactions with regulatory authorities, and risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Contact

Company Contact:

Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com 

For Investor Inquiries:

Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com 

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/488af120-ee08-414a-a5fe-965695b484cc
https://www.globenewswire.com/NewsRoom/AttachmentNg/e69c9b5d-e22b-41bd-be62-5ff390493f8c
https://www.globenewswire.com/NewsRoom/AttachmentNg/83051af8-0e5e-44b3-9554-ee9f823c3c28
https://www.globenewswire.com/NewsRoom/AttachmentNg/07090e88-5325-40fa-8c43-8ceae8ccbc16

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
13 NOVEMBER 2026

Please find below the Highlights and Chairman’s commentary from the Richemont FY27 – Interim Results announcement.

RICHEMONT POSTS STRONG RESULTS FOR THE SIX-MONTH PERIOD ENDED 30 SEPTEMBER 2026 DRIVEN BY SUSTAINED DOUBLE-DIGIT SALES GROWTH

Group highlights

• Group sales at € 12.3 billion, up by 17% at constant rates (+16% actual), including sustained Q2 growth of +13%
• Operating profit of € 3.1 billion, fuelled by strong sales growth against a context of persistently elevated raw material costs; € 2.9 billion excluding € 229 million positive tariff-related one-time items
• Strengthening the enduring appeal of our Maisons through unwavering product creativity and craftsmanship, alongside strategic investment in our network and manufacturing capabilities

Financial highlights

• Double-digit growth across most regions throughout H1, led by Japan, the Americas and Asia Pacific
• Broad-based strength across business areas in H1, including in Q2 against elevated comparatives
  • Excellent performance at Jewellery Maisons, with sales up by 19% at constant exchange rates (+18% actual)
  • Robust sales at Specialist Watchmakers over the period, up by 10% at constant exchange rates (+9% actual)
  • Continued momentum in the ‘Other’ business area, up by 9% at constant and actual exchange rates
• Operating profit up by 33%, or by 38% at constant exchange rates
• Operating margin at 25.5%, up by 330bps; 23.6% (+140bps) excluding the positive contribution from one-time items
• € 2.5 billion profit for the period, up by 39%
• Strong net cash position at € 7.7 billion, reflecting € 2.5 billion cash flow generated from operating activities, a € 0.4 billion cash inflow from disposal of the Avolta stake and the increased dividend payment

Key financial data (unaudited)

Six months ended 30 September	2026	2025	change
Sales	€ 12 282 m	€ 10 619 m	+16%
Gross profit	€ 8 165 m	€ 6 939 m	+18%
Gross margin	66.5%	65.3%	+120 bps
Operating profit	€ 3 129 m	€ 2 358 m	+33%
Operating margin	25.5%	22.2%	+330 bps
Profit for the period from continuing operations	€ 2 528 m	€ 1 796 m	+41%
Profit for the period from discontinued operations	–	€ 17 m
Profit for the period	€ 2 528 m	€ 1 813 m	+39%
Earnings per ‘A’ share/10 ‘B’ shares, diluted basis	€ 4.29	€ 3.08
Cash flow generated from operating activities	€ 2 500 m	€ 1 854 m	+€ 646 m
Net cash position	€ 7 729 m	€ 6 519 m

Chairman’s commentary 

Overview of results
In the first six months of the financial year, Richemont delivered strong results in a volatile geopolitical and macroeconomic environment. The Group posted sales of € 12.3 billion, an increase of 16% at actual exchange rates and 17% at constant exchange rates. After a particularly strong Q1 in which sales rose by 20% at constant rates, the Group maintained momentum with growth of 13% in Q2 against a high comparative of +14% in the prior-year period. Both in the first half and the second quarter, all business areas performed strongly, with double-digit rises across every region except Middle East & Africa – a broad-based result driven by disciplined execution and the Group’s diversified growth engines.

Sales rose across all distribution channels in the first half. Retail and online sales were particularly strong, leading to a 78% share of direct-to-client sales, a 2-percentage point increase versus the prior-year period.

The Group’s Jewellery Maisons – Buccellati, Cartier, Van Cleef & Arpels and Vhernier – posted an 18% increase in sales in the first six months of the year. At constant exchange rates, sales were up by 19% in the first half, with Q2 up by 14%. This excellent performance was driven by strong demand for iconic jewellery and watch collections across geographies, buoyed by the appeal of product novelties combined with a commitment to delivering lasting value to our clients. Against a backdrop of elevated raw material costs, the Jewellery Maisons preserved their disciplined approach to pricing and continued investing to safeguard future growth. On the back of their strong sales performance, the Jewellery Maisons delivered a € 3.2 billion operating result in the first half, up from € 2.5 billion in the prior-year period. Operating margin stood at 35.3%, or 33.4% excluding positive one-time items.

The Group’s Specialist Watchmakers recorded sales of € 1.7 billion, up by 9%. At constant exchange rates, sales in the six-month period grew by 10%, and +12% in the second quarter. Although recovery is unlikely to be linear in an environment that continues to be challenging for the industry, I am pleased to see our Specialist Watchmakers delivering growth for over a year now. In the first half, most Maisons grew, led by Vacheron Constantin, Jaeger-LeCoultre and A. Lange & Söhne whose sales were supported by iconic lines and impactful novelties. This performance was achieved against continued soft demand in China. Whilst sales were stable in Asia Pacific, they rose by double digits across all other regions, led by strength in the Americas and Japan. Operating profit reached € 150 million, up from € 50 million in the prior-year period, largely resulting from solid sales growth combined with effective cost discipline. Operating margin stood at 8.8%, or 7.7% excluding positive one-time items.

Sales at our ‘Other’ business area were up by 9% at actual and constant exchange rates, with steady momentum throughout the first half. Sales at Fashion & Accessories Maisons experienced a similar pattern, supported by double-digit growth in ready-to-wear. The performance was primarily driven by double-digit growth at Alaïa and Peter Millar, combined with improved momentum at Montblanc. Overall, the ‘Other’ business area recorded a € 12 million operating loss. Excluding positive one-time items, the operating loss of the business area was broadly stable compared to the prior-year period with modest improvement in F&A operating result.

Operating profit from continuing operations came in at € 3.1 billion, up by 33%. Excluding € 229 million positive one-time items, operating profit stood at € 2.9 billion. Whilst elevated raw material costs continued to weigh on the gross margin, profitability benefitted from the positive effect of the strong top line expansion. Profit for the period increased to € 2.5 billion, up by 39% compared to the prior-year period.

Finally, our robust net cash position amounted to € 7.7 billion at 30 September 2026. This was driven by a € 2.5 billion cash flow from operating activities, a € 0.4 billion cash inflow from the disposal of the Group’s stake in Avolta, and also accounted for the significantly increased dividend payment in September of this year.

Annual General Meeting and Board changes

On 9 September 2026, the Board announced the appointment of Anton Rupert as Non-Executive Co-Deputy Chairman, serving alongside Bram Schot, who has held the position since 2024. This appointment is an important step in our long-term succession planning and reflects our commitment to sound governance.

The two roles are designed to be complementary. Anton oversees matters relating to the Maisons’ Strategic Product and Communications Committee, helping to ensure continuity in the creative vision and product excellence that define our Maisons and underpin their long-term success. Bram assumes responsibility for Board and Committee governance matters, including the effective coordination of the Board’s committees and oversight of the Group’s corporate governance framework.

A long-term perspective, sound governance and a commitment to creativity and craftsmanship remain central to Richemont’s culture. These principles have served our Maisons well and will continue to guide us.

At the Annual General Meeting (‘AGM’) held on 9 September 2026, all Board members standing for re-election were re-elected for a further one-year term. Wendy Luhabe was also reappointed as the ‘A’ shareholders’ representative.

For the third consecutive year, shareholders approved the Group’s annual Non-Financial Report, which sets out our approach to responsible business.

Concluding remarks 

The Group delivered a strong first half, carried by the sustained excellent performance of our Jewellery Maisons, robust growth at our Specialist Watchmakers, and solid momentum at our Fashion & Accessories Maisons despite a challenging fashion market. These results reflect the strength of our long-term strategy and demonstrate the enduring attractiveness and relevance of our Maisons’ positioning.

Performance was broad-based across regions, with growth recorded across all major markets except the Middle East and Africa. Our thoughts remain with colleagues, clients and their loved ones affected by the ongoing conflict in the Middle East.

Sales growth and disciplined operational execution enabled the Group to increase profitability despite continued pressure from elevated raw material costs. Our strong cash position also enabled us to continue investing in the long-term development of our Maisons.

Whilst we cannot predict what lies ahead, we expect the macroeconomic and geopolitical environment to remain volatile for the foreseeable future. These conditions reinforce the importance of maintaining operational discipline whilst continuing to invest in the people, creativity and craftsmanship on which our Maisons’ long-term success depends, enabling us to create enduring value for all our stakeholders.

Johann Rupert
Chairman

Compagnie Financière Richemont SA

About Richemont

At Richemont, we craft the future. Our unique portfolio includes prestigious Maisons distinguished by their creativity and craftsmanship. Richemont’s ambition is to nurture its Maisons and businesses and enable them to grow and prosper in a responsible, sustainable manner over the long term.

Richemont operates in three business areas: Jewellery Maisons with Buccellati, Cartier, Van Cleef & Arpels and Vhernier; Specialist Watchmakers with A. Lange & Söhne, IWC Schaffhausen, Jaeger-LeCoultre, Panerai, Piaget, Roger Dubuis and Vacheron Constantin; and Other, primarily Fashion & Accessories Maisons with Alaïa, Chloé, Delvaux, dunhill, G/FORE, Gianvito Rossi, Montblanc, Peter Millar, Purdey, Serapian as well as TimeVallée and Watchfinder & Co. Find out more at https://www.richemont.com/.

Disclaimer

This document contains forward-looking statements as that term is defined in the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not guarantees of future performance. Richemont’s forward-looking statements are based on management’s current expectations and assumptions regarding the Company’s business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. Our retail stores are heavily dependent on the ability and desire of consumers to travel and shop and a decline in consumers traffic could have a negative effect on our comparable store sales and/or average sales per square foot and store profitability resulting in impairment charges, which could have a material adverse effect on our business, results of operations and financial condition. Reduced travel resulting from economic conditions, retail store closure orders of civil authorities, travel restrictions, travel concerns and other circumstances, including disease epidemics and other health-related concerns, could have a material adverse effect on us, particularly if such events impact our customers’ desire to travel to our retail stores. International conflicts or wars, including resulting sanctions and restrictions on importation and exportation of finished products and/or raw materials, whether self-imposed or imposed by international countries, non-state entities or others, may also impact these forward-looking statements. If international tariffs are imposed or increased, materials and goods that Richemont imports may face higher prices, which could lead to reduced margins or increased prices that could cause decreased consumer demand. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. Actual results may differ materially from the forward-looking statements as a result of a number of risks and uncertainties, many of which are outside the Group’s control. Richemont does not undertake to update, nor does it have any obligation to provide updates of, or to revise, any forward-looking statements.

© Richemont 2026 

This announcement does not contain full details and should not be used as a basis for any investment decision in relation to the Company’s shares. Please find the full announcement available in PDF below: 

Richemont FY27 Interim Results PDF EN | Richemont FY27 Interim Results PDF FR (abridged)

COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the share buy-back program announced on August 21, under which the Company intends to repurchase own shares for up to DKK 750 million. The second tranche will comprise buy-back of shares for up to DKK 250 million.

The purpose of the new share buy-back program is to adjust the capital structure, through subsequent cancellation of shares repurchased under this program, subject to any necessary additional corporate resolutions, as applicable.

The share buy-back program is initiated pursuant to the authorization granted at the annual general meeting on April 21, 2026, and in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Bavarian Nordic has appointed Danske Bank as lead manager to execute the share buy-back in accordance with the terms of the program and with authorization to make trading decisions independently and without influence of Bavarian Nordic.

Terms of the program

• The share buy-back program will commence on November 13, 2026, and will be completed by January 15, 2027, at the latest.
• Shares of up to a maximum aggregate purchase price of DKK 250 million may be repurchased.
• A maximum of 2,000,000 shares will be repurchased within the duration of the program.
• The maximum number of shares, which can be purchased on any single trading day, may not exceed 25% of the average daily trading volume of Bavarian Nordic shares traded on Nasdaq Copenhagen during the preceding 20 trading days before the trading day.
• The shares may not be purchased at a price exceeding the higher of the price of the last independent trade, or the highest independent purchase bid on Nasdaq Copenhagen.

Details of transactions under the program will be published weekly after commencement and at completion of the program.

Prior to the initiation of this program, Bavarian Nordic held 4,664,037 treasury shares, corresponding to 5.88% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Company Announcement no. 55 / 2026

Attachment

• Bavarian Nordic Launches Next Tranche of DKK 750 Million Share Buy-Back Program

PRESS RELEASE November 13, 2026

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION TO ANY U.S. PERSON (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED) OR IN OR INTO CANADA, JAPAN, SOUTH AFRICA, AUSTRALIA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS PRESS RELEASE

RENAULT GROUP SUCCESSFULLY ISSUES A €750 MILLION BOND

Boulogne-Billancourt, November 13, 2026 – Renault Group announces the successful placement of a 750 million euros bond issue maturing February 19, 2032, and carrying a coupon of 5%.

This issue was largely oversubscribed, underlying strong credit investors’ confidence in Renault Group’s robust financial position, as evidenced by its improved credit rating and the return into investment grade category at both S&P Global Ratings and Moody’s, and in the sound implementation of its strategic plan, futuREady.

This issuance allows Renault Group to benefit from attractive market conditions and will be used for general corporate purposes including the anticipation of the refinancing of some of its upcoming maturities.

RENAULT GROUP RELATIONS MEDIAS

François Rouget +33 6 23 68 07 88 francois.rouget@renault.com

RENAULT INVESTORS RELATIONS

Florent Chaix +33 6 07 88 83 05 florent.chaix@renault.com

About Renault Group
Renault Group is at the forefront of a mobility that is reinventing itself. The Group relies on the complementarity of its three automotive brands – Renault, Dacia, Alpine – and its financial captive Mobilize Financial Services to offer sustainable and innovative mobility solutions to its customers. Established in more than 100 countries, Renault Group sold 2.337 million vehicles in 2025. It employs more than 100,000 people who embody its Purpose every day, so that mobility brings people closer.

Ready to pursue challenges both on the road and in competition, the Group is committed to an ambitious and value-generating transformation focused on the development of new technologies and services, and a new range of even more competitive, balanced, and electrified vehicles. In line with environmental challenges, Renault Group’s ambition is to achieve net zero carbon in Europe by 2040 and worldwide by 2050.

More information: https://www.renaultgroup.com/en/

IMPORTANT INFORMATION – DISCLAIMER
This press release does not constitute an offer, or an invitation to apply for, or an offer or invitation to purchase or subscribe for any securities either in the United States or in any other jurisdiction which may be subject to restrictions. These securities will not be and have not been registered under the U.S. Securities Act of 1933, as amended and may not be offered or sold in the United States of America unless they are registered or exempt from registration. There will be no public offer of securities in the United States. This press release does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”). This press release does not constitute an offer of securities in France or in any other country. The bonds are the subject of a private placement in France to qualified investors as defined in Article 2(e) of the Prospectus Regulation and in accordance with Article L.411-2 of the Monetary and Financial Code, and outside France (excluding the United States of America, Australia, Canada, South Africa and Japan). Renault Group will undertake no action as part of this placement with a view to making an offer to the public (other than to qualified investors) in France or abroad. In the United Kingdom, this press release may be sent to qualified investors as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024 only under circumstances wherein section 21(1) of the Financial Services and Markets Act 2000 does not apply. The dissemination of this press release in any country where such dissemination could constitute a violation of applicable legislation is prohibited.

Attachment

• 20261113_ GB_Renault Group_Eurobond

COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the third quarter and first nine months of 2026.

Financial highlights

• Revenue in the third quarter was DKK 1,805 million, compared to DKK 1,795 million in the third quarter of 2025.
• Travel Health revenue increased by 22% (32% when adjusting for discontinued partnerships) to DKK 1,144 million, primarily driven by continued strong RabAvert/Rabipur sales (DKK 886 million, +37%) and supported by the continued launch of Vimkunya (DKK 73 million, +146%).
• Public Preparedness revenue reached DKK 606 million in the third quarter, in line with expectations targeting DKK 2,500 million for the full year.
• EBITDA in the third quarter was exceptionally strong with DKK 621 million, corresponding to an EBITDA margin of 34.4%. Gross margin reached 51.9% driven by the strong topline and an advantageous product and market mix.

Total revenue for first nine months was DKK 4,897 million, an increase of 2%, reflecting the strong growth in Travel Health (+24%) and the year-over-year lower Public Preparedness revenue (-20%) in line with expectations. EBITDA for the first nine months reached DKK 1,711 million, corresponding to an EBITDA margin of 34.9%, driven by the extraordinary performance in the second and third quarters and substantially above our annual EBITDA margin ambition of 25-30%.

Full-year guidance maintained

• The upgraded full-year guidance for 2026, issued on October 8, is maintained. Total revenue of approximately DKK 6,100 million is expected and the EBITDA margin is expected to reach approximately 32%, reflecting the impact of revenue phasing and increased investment levels in the fourth quarter.

DKK million	Q3 2026	Q3 2025	9M 2026	9M 2025	2026 Guidance
Revenue	1,805	1,795	4,897	4,793	~6,100
EBITDA margin	34%	29%*	35%	31%*	~32%

* Excluding other net operating income of DKK 810 million from the sale of the Priority Review Voucher which was recognized in Q3 2025.

Strong performance provides a solid foundation for growth
Commenting on the interim results, Tarja Stenvall, President & Chief Executive Officer of Bavarian Nordic said:

“Bavarian Nordic has delivered solid performance in the first nine months of 2026, driven by continued growth in Travel Health and solid execution in Public Preparedness. Our results reflect the strength of our vaccine portfolio and our ability to reach more people with important vaccines, while supporting governments in strengthening their preparedness against infectious diseases. Having recently joined Bavarian Nordic, I see a company with deep expertise, strong capabilities and a proven track record of delivery. My immediate priority is to maintain this momentum while taking a thoughtful approach to shaping the company’s next phase of growth.”

Business highlights

• In August, the European Commission approved the use of MVA-BN mpox and smallpox vaccine for children 2 to less than 12 years of age.
• In September, Tarja Stenvall was appointed new CEO, effective as of October 15. She succeeds Paul Chaplin, who stepped down after serving 27 years in the company, the last 12 years as CEO.
• In July, the Company completed its DKK 500 million share buy-back program launched in January. A new share buy-back program of up to DKK 750 million was announced in September, with the initial DKK 250 million tranche completed in October.
• In November, Henrik Juuel, Chief Financial Officer since 2018, announced that he will step down in April 2027. The Board has initiated a search process to identify the Company’s next CFO.

Conference call and webcast
The management of Bavarian Nordic will host an investor/analyst call today at 2 pm CET (8 am EST) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via https://edge.media-server.com/mmc/p/aiahpzpi/. To join the Q&A session, please register in advance via https://register-conf.media-server.com/register/BIcb3701d8b1fc4cc5af43e03b3b9eaf8a.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Company Announcement no. 54 / 2026

Attachments

• Bavarian Nordic Q3 2026 Report
• Bavarian Nordic Reports Strong Travel Health Growth in the Third Quarter and Confirms Solid Momentum for the Rest of the Year

COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that Henrik Juuel has informed the Board of Directors of his decision to step down as Chief Financial Officer. Henrik Juuel will remain in his role until end of April 2027 to ensure a smooth transition and support the onboarding of his successor. The Board has initiated a search process to identify the Company’s next CFO.

Since joining Bavarian Nordic in 2018, Henrik Juuel has been a key contributor to the Company’s transformation into a leading global vaccine company. Under his financial leadership, the Company successfully executed several strategic acquisitions, expanding its commercial footprint to support long-term growth and value creation. Henrik has been instrumental in strengthening the Company’s financial position, supporting strong cash flow generation and a balanced approach to capital allocation.

Reflecting on his tenure with Bavarian Nordic, Henrik Juuel said: “After eight rewarding years with Bavarian Nordic, I have decided that the time is right for me to step down from my role as CFO and create more space for family and personal priorities. It has been a privilege to work alongside so many talented and dedicated colleagues and to contribute to the company’s development during a period of significant growth and change. I would like to thank the Board of Directors, the Executive Management team, our employees, and our shareholders for their trust, support, and partnership over the years. I remain firmly committed to the company, focused on supporting Tarja Stenvall in her role as our new CEO, and to secure a smooth handover to my successor. I am pleased to leave Bavarian Nordic in a very strong financial position and with a talented team to deliver on its ambitions, and I look forward to following its continued success.”

Chair of the Board of Directors, Anne Louise Eberhard, said: “On behalf of the Board, I would like to thank Henrik for his invaluable contribution to Bavarian Nordic over the past eight years. Throughout his tenure, he has provided exceptional financial leadership and strategic counsel during a period of significant growth and transformation for the Company. His dedication, sound judgment, and long-term perspective have helped strengthen the foundation for Bavarian Nordic’s next phase of growth. Henrik’s retirement from executive life is truly well deserved, and I wish him all the best in this next chapter of his life.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58

Contact media:
Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33

Company Announcement no. 53 / 2026

This announcement contains publication of inside information pursuant to Article 17 of the EU Market Abuse Regulation.

Attachment

• Henrik Juuel to Step Down as Chief Financial Officer of Bavarian Nordic in 2027

Paris, 13 November 2026

Notice to holders of the bonds convertible into new shares and/or exchangeable for existing shares (OCEANE) issued on 23 March 2021 (ISIN FR0014002JO2) (the “Bonds”) in relation to a Change of Control constituting a Put Event

Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the terms and conditions of the Bonds (the “Conditions”).

The holders of the Bonds issued by Fnac Darty, listed on Euronext Access Paris, are hereby informed, in accordance with Article 1.9.1.5 and Article 2.9 of the Conditions, of the occurrence of a Change of Control. This is the Put Event Notice in relation to such Change of Control.

The nature of the Change of Control and circumstances giving rise to it are as follows:

Pursuant to the results of the voluntary tender offer on the shares and Bonds of Fnac Darty filed by EP FR HoldCo which were published by the AMF on 10 November 2026, EP FR HoldCo holds (together its affiliate VESA, with whom it is acting in concert) with 69.3% of the share capital and theoretical voting rights of the Company, resulting in a Change of Control, it being specified that EP FR HoldCo already held, by way of assimilation through its affiliate VESA, 28.45% of the share capital and theoretical voting rights of the Company prior to the opening of the tender offer.

Fnac Darty reminds the Bondholders of the timetable and procedure for the exercise relating to the early redemption option of the Bonds.

Each Bondholder will have the right to require the early redemption on 18 December 2026 (the “Optional Redemption Date”) in whole or in part of the Bonds held by it at a price per Bond equal to the Early Redemption Price (as defined below) (the “Put Event Option”), provided that the Put Event Option is exercised during the period of at least fifteen (15) Business Days commencing on and (including) the date on which this Put Event Notice is given, i.e., from 13 November 2026 (included) until 11 December 2026 (included) (the “Put Option Period”).

To exercise the Put Event Option, each Bondholder must transfer (or cause to be transferred by its Account Holder) its Bonds to be so redeemed to the account of the Centralising Agent (now Uptevia) (which details are as follows: Uptevia Euroclear participant 023  email: OSTCENTRAPRIMAIRE@uptevia.com), for the account of Fnac Darty together with a duly signed and completed notice of exercise in the form attached hereto as Schedule 1 (the “Put Option Notice”). The Put Option Notice shall (i) be delivered by each Bondholder to its Account Holder and (ii) be required to be received by the Centralising Agent, in each case on or before the last day of the Put Option Period, it being specified that the Put Option Notice shall be deemed to have been so received by the Centralising Agent on the day on which the last of the two conditions (a) and (b) below is satisfied (and further provided that if any such condition is satisfied on a day which is not a Business Day, or after 5:00 p.m. (Paris time) on a Business Day, it shall be deemed to have been satisfied instead on the following Business Day):
(a) the receipt by the Centralising Agent of the Put Option Notice sent by the relevant Account Holder in the books of which the Bonds are held in a securities account;
(b) the transfer of the Bonds to the Centralising Agent by the relevant Account Holder.

For the avoidance of doubt, any Put Option Notice that is so received (or deemed to be so received) by the Centralising Agent after 5:00 p.m. (Paris time) on the last day of the Put Option Period (being 11 December 2026) shall be deemed to be null and void.

The Optional Redemption Date for the Bonds has been set at 18 December 2026 at a price per Bond equal to €81.17985 (the “Early Redemption Price”), comprised of the par value (i.e., €81.03), plus accrued interest of €0.14985. Redemption will be made in cash.

Once validly presented by a Bondholder to its Account Holder, the early redemption request will be irrevocable, and Fnac Darty will be bound to redeem on the Optional Redemption Date all the Bonds included in each request so forwarded to the Centralising Agent.

As of the date of this Put Event Notice, €45,708,860.94 in aggregate nominal value of the Bonds remain outstanding.

For the avoidance of doubt, Fnac Darty reminds the Bondholders that the early redemption of their Bonds in accordance with the terms of this Put Event Notice is a separate procedure from the tender of their Bonds into the reopened voluntary tender offer filed by EP FR HoldCo.

Investor Relations Contact: investisseurs@fnacdarty.com

Schedule 1

Put Option Notice

To:
[[●]
[Address]
Attention: [●]

Email: [●]]

(the “Account Holder”)

            [●] 2026

Dear Madam, Dear Sir,

We refer to the put event notice dated 13 November 2026 (the “Put Event Notice”) issued by Fnac Darty SA, relating to the timetable and procedure for exercising the put option on the bonds convertible into new shares and/or exchangeable for existing shares (OCEANE) issued on 23 March 2021 (ISIN FR0014002JO2) (the “Bonds”), and to the terms and conditions of the Bonds (the “Conditions”).

Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the Conditions.

Through the Put Event Notice we were informed, in accordance with Article 1.9.1.5 and Article 2.9 of the Conditions, of the occurrence of a Change of Control, and therefore, our right as Bondholder to require the early redemption on the Optional Redemption Date of all or part of the Bonds held by us (the “Put Event Option”), provided that the Put Event Option is exercised during the period of at least fifteen (15) Business Days commencing on and (including) the date on which the Put Event Notice is given, i.e., from 13 November 2026 (included) until 11 December 2026 (included) (the “Put Option Period”).

By this letter (the “Put Option Notice”), we confirm our wish to have redeemed [number of bonds redeemed] Bonds owned by us and to transfer them to the account of the Centralising Agent (UPTEVIA) (which details are as follows: Uptevia Euroclear participant 023  email: OSTCENTRAPRIMAIRE@uptevia.com) for the account of Fnac Darty.

We hereby request that, as soon as practicable upon receipt of this Put Option Notice and in any event before 5:00 p.m. (Paris time) on the final Business Day of the Put Option Period, in your capacity as Account Holder, you transfer such [number of bonds redeemed] Bonds owned by us to the account of the Centralising Agent and notify the Centralizing Agent of our exercise of the Put Event Option according with the terms of this Put Option Notice (including by delivering any copies of this Put Option Notice to the Centralizing Agent).

Payment in respect of any such Bond may be made by transfer to the following bank account, it being specified that such bank account is a Euro account with a bank in a city in which banks have access to the TARGET2 System:

Name of holder: [●]

Address of holder: [●]

IBAN: [●]

BIC: [●]

We also hereby acknowledge that this Put Option Notice is irrevocable.

[Bondholder]

Attachment

• 20261113_Oasis – Put Event Notice OCEANEs_mel